The Freedom Stack Research Data at a Glance Overview A 5-vial research stack 1x GLP3-R 30mg, 2x SS-31 50mg, 2x KLOW 80mg
In this study, the effect size identified for reduction in stroke risk (HR 0.74) is comparable to or exceeds that of meta-analyses investigating the effects of lowering blood pressure (RR 0.73), treating hyperlipidemia (RR 0.79), and other interventions in people with T2D [30], highlighting the benefits that can be achieved by adding GLP-1 RAs to antihyperglycemic regimens
This is not a single-target drug
Cageside Seats, for Pro Wrestling fans
The FDA reports include nausea, vomiting, diarrhea, abdominal pain, constipation, injection site reactions, and more severe outcomes including pancreatitis requiring hospitalization, gallbladder disease, severe hypoglycemia, and acute kidney injury